Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.49 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.40 |
| ▸ | CDK6 | Q00534 | 2/20 | 0.38 |
| ▸ | CDK1 | P06493 | 1/20 | 0.38 |
| ▸ | CDK4 | P11802 | 1/20 | 0.38 |
| ▸ | SYK | P43405 | 4/20 | 0.38 |
| ▸ | FLT3 | P36888 | 3/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
| ▸ | TYK2 | P29597 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL389525 | 0.88 | GPR119 (0.50) | GPR119SYK | |
| SCHEMBL4722419 | 0.82 | GPR119 (0.41) | GPR119CDK6CDK1CDK4SYK | |
| SCHEMBL1070555 | 0.80 | GPR119 (0.47) | GPR119CDK6FLT3CDK2 | |
| SCHEMBL5046848 | 0.79 | GPR119 (0.44) | GPR119ERBB2CDK6FLT3CDK2 | |
| SCHEMBL1830976 | 0.77 | GPR119 (0.45) | GPR119CDK6FLT3CDK2 | |
| SCHEMBL5048945 | 0.76 | GPR119 (0.57) | GPR119ERBB2CDK6CDK4FLT3 | |
| SCHEMBL5263512 | 0.76 | GPR119 (0.51) | GPR119CDK6FLT3CDK2 | |
| SCHEMBL3866032 | 0.76 | GPR119 (0.48) | GPR119ERBB2CDK6FLT3CDK2 | |
| SCHEMBL13685341 | 0.75 | GPR119 (0.53) | GPR119ERBB2CDK6FLT3CDK2 | |
| SCHEMBL1832092 | 0.75 | GPR119 (0.44) | GPR119CDK6FLT3CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2004157-A2 | USE OF GPR119 RECEPTOR AGONISTS FOR INCREASING BONE MASS AND FOR TREATING OSTEOPOROSIS, AS WELL AS COMBINATION THERAPY RELATING THERETO | Arena Pharmaceuticals, Inc. (US) | 2008-12-24 | — | — | EP | disclosed |
| WO-2007120702-A2 | USE OF GPR119 RECEPTOR AGONISTS FOR INCREASING BONE MASS AND FOR TREATING OSTEOPOROSIS, AND COMBINATION THERAPY RELATING THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2007-10-25 | — | — | WO | disclosed |